Cellceutix Corp. has entered into a Confidential Disclosure Agreement (CDA) with a large pharmaceutical company for KM-391, its novel compound being developed as a treatment for autism. Cellceutix chief executive officer, Leo Ehrlich, commented, “This is simply another vote of confidence from large pharma as to the strength of our pipeline and a testament to the attention that we are receiving on a global level. While signing a CDA does not imply or guarantee that a licensing deal or any oth...